Cytokine antagonists have only been tested in short-term clinical pharmacological studies. More relevant clinical studies are ongoing. Other possible immunomodulatory treatments are in an even less advanced development stage. Potential determinants of this rise are the increasing obesity in affluent populations, exposure to diesel and other particles, and the reduced burden of infections. Their considerable benefit far outweighs their minimal risk of producing clinically relevant adverse effects.
Optimal use involves individualization of dose and use of minimal effective doses.
Partners in Asthma Speaker to be announced.